Validation of Immunotherapy Response Score (IRS) for Predicting Pembrolizumab Monotherapy Benefit in First Line (1L) Non-small Cell Lung Cancer (NSCLC)
JOURNAL OF THORACIC ONCOLOGY(2024)
AI 理解论文
溯源树
样例

生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要
JOURNAL OF THORACIC ONCOLOGY(2024)